PLK1 and cancer: The higher sensitivity of TP53-mutated cancer cell lines to these compounds could be attributed to the SL interactions between the targets of these compounds and TP53. Actually, the compounds' targets such as PLK1 and EGFR have been identified to be SL with TP53 by this method.